Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terry A Jacobson

Showing results (171-180 of 182) with videos related to

Pageof 19
Sort By:
Journal of the American Heart Association|March 9, 2022
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCIBenjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.
Circulation|November 5, 2020
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization AnalysesBenjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.
JAMA Network Open|February 14, 2022
Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin TreatmentWilliam S Weintraub, Deepak L Bhatt, Zugui Zhang, et al.
Journal of Clinical Lipidology|October 11, 2011
Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialistsMichael H Davidson, Christie M Ballantyne, Terry A Jacobson, et al.
European Journal of Preventive Cardiology|September 22, 2025
Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-ITChen Gurevitz, Deepak L Bhatt, Robert P Giugliano, et al.
Circulation|October 28, 2021
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABGSubodh Verma, Deepak L Bhatt, Ph Gabriel Steg, et al.
Annals of Internal Medicine|July 4, 2012
Effect of a pharmacist intervention on clinically important medication errors after hospital discharge: a randomized trialSunil Kripalani, Christianne L Roumie, Anuj K Dalal, et al.
JACC. Advances|June 26, 2025
Prevalence and Correlates of Lipoprotein(a) Testing in a Diverse Cohort of U.S. AdultsAlexander C Razavi, LaTonia C Richardson, Fátima Coronado, et al.
European Heart Journal|February 20, 2015
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and ManagementErik S Stroes, Paul D Thompson, Alberto Corsini, et al.
European Heart Journal|May 3, 2018
Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataractFrançois Mach, Kausik K Ray, Olov Wiklund, et al.
Pageof 19

Showing results (171-180 of 182) with videos related to

Sort By:
Pageof 19
Journal of the American Heart Association|March 9, 2022
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCIBenjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.
Circulation|November 5, 2020
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization AnalysesBenjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.
JAMA Network Open|February 14, 2022
Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin TreatmentWilliam S Weintraub, Deepak L Bhatt, Zugui Zhang, et al.
Journal of Clinical Lipidology|October 11, 2011
Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialistsMichael H Davidson, Christie M Ballantyne, Terry A Jacobson, et al.
European Journal of Preventive Cardiology|September 22, 2025
Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-ITChen Gurevitz, Deepak L Bhatt, Robert P Giugliano, et al.
Circulation|October 28, 2021
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABGSubodh Verma, Deepak L Bhatt, Ph Gabriel Steg, et al.
Annals of Internal Medicine|July 4, 2012
Effect of a pharmacist intervention on clinically important medication errors after hospital discharge: a randomized trialSunil Kripalani, Christianne L Roumie, Anuj K Dalal, et al.
JACC. Advances|June 26, 2025
Prevalence and Correlates of Lipoprotein(a) Testing in a Diverse Cohort of U.S. AdultsAlexander C Razavi, LaTonia C Richardson, Fátima Coronado, et al.
European Heart Journal|February 20, 2015
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and ManagementErik S Stroes, Paul D Thompson, Alberto Corsini, et al.
European Heart Journal|May 3, 2018
Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataractFrançois Mach, Kausik K Ray, Olov Wiklund, et al.
Pageof 19